bioMérieux is committed to making personalized medicine a reality by building partnerships to develop theranostics for infectious diseases, cancer and cardiovascular diseases
Some collaborations include Merck & Co., Ipsen and GSK (two development projects). bioMérieux has made a sustained investment in high medical value biomarkers through in-house R&D programs, licensing and research collaborations.
Theranostics development also leverages bioMérieux's unique hybrid business strategy: the high complexity CLIA lab of its subsidiary, bioTheranostics, allied with bioMérieux's global IVD business, supports aggressive development timelines while ensuring test availability wherever the drug is sold.